Skip to main content

Collegium Pharmaceutical, Inc.

corporate_fare Company Profile

Collegium Pharmaceutical, Inc.

COLL·NASDAQ·Life Sciences·CIK 0001267565

The company is a diversified biopharmaceutical company focused on improving the lives of people with serious medical conditions. It develops, licenses, and acquires differentiated products for attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. The company commercializes its products in the United States. Key products include Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively "Nucynta Products"), and Symproic. Jornay PM is a central nervous system (CNS) stimulant prescription medicine containing methylphenidate HCl, a Schedule II methylphenidate. It was approved by the U.S. Food and Drug Administration (FDA) in August 2018 for treating ADHD in people six years of age and older. Jornay PM is currently the only FDA-approved stimulant medication dosed in the evening. The company acquired Ironshore, which developed Jornay PM, on September 3, 2024, expanding its business into neuropsychiatry via the ADHD market. Belbuca is a buccal film containing buprenorphine, a Schedule III opioid. It was FDA-approved in October 2015 for severe and persistent pain requiring extended daily opioid analgesic treatment when other options are inadequate. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone, a Schedule II opioid. It uses the DETERx technology platform, which combines an active opioid ingredient with a fatty acid and waxes to form microspheres in a capsule. These wax-based microspheres are designed to resist particle size reduction and dose dumping when physically and chemically manipulated, aiming to deter abuse and misuse like crushing, chewing, heating, and injecting.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for COLL at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Collegium Pharmaceutical Projects 4% Revenue Growth for 2026, Refinances Debt for Significant Interest Savings

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$780.57M
Net Income
$62.87M
Diluted EPS
$1.73
Op. Cash Flow
$329.32M
Free Cash Flow
$327.58M
Gross Profit
$463.26M
Operating Income
$179.64M
Cash & Equivalents
$231.25M
Debt / Equity
0.00×
Net Margin
8.1%
Shares Outstanding
31.71M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-011992
$24.72
52-week range · as of 2026-11-05 $21.43 – $50.79
Market cap
$768.18M
Volume
528K (0.8× avg)
3-mo avg 630.7K
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed COLL - Filings & News (Page 2)

COLL
Jan 08, 2026, 8:06 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.62
Real-time Price: $24.72 info
Change: -$22.90 (-48%) info
Market Cap: $768.184M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets